Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled,
parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on
therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with
moderate-to-severe asthma.